ACE and COVID-19: In the same month, NEJM published the results of another multicentre observational study by Mandeep R. Mehra et al. [144]: in a cohort of 8910 hospitalized COVID-19 patients, use of ACE inhibitors was associated with better survival (odds ratio for mortality 0.33; 95% CI 0.20–0.54).